BridgeBio Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2830 bridgebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma, Inc.

Viatris Gears Up to Report Q2 Earnings: What's in the Cards? - Aug 4th, 2026 9:37 am
BridgeBio Pharma (BBIO) Stock Looks Priced At A Premium Despite 148% Returns - Aug 4th, 2026 3:14 am
BridgeBio Pharma (BBIO) Wins FDA Review For Encaleret In ADH1 - Aug 3rd, 2026 7:11 pm
BridgeBio Pharma (BBIO) After Its $2.21b Stock Filing Is It A Buy Or Priced In - Aug 3rd, 2026 1:09 pm
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET - Aug 3rd, 2026 5:30 am
1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree. - Aug 2nd, 2026 4:15 am
Alnylam plunges as earnings deliver ‘one-two punch’ - Jul 30th, 2026 10:12 am
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? - Jul 28th, 2026 8:00 am
FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug - Jul 23rd, 2026 11:12 am
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 - Jul 22nd, 2026 5:30 am
Yext, Mission Produce, and 3 More Stocks See Action From Activist Investors - Jul 17th, 2026 2:11 pm
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo - Jul 14th, 2026 8:42 am
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions - Jul 13th, 2026 10:25 am
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Jul 10th, 2026 2:01 pm
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High - Jul 10th, 2026 10:21 am
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act? - Jul 10th, 2026 6:14 am
BridgeBio Pharma (BBIO) Is Up 16.8% After Phase 3 Infigratinib Win And $934M Raise - Jul 10th, 2026 6:13 am
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last? - Jul 10th, 2026 3:33 am
BridgeBio stock jumps after rival heart drug fails key trial - Jul 9th, 2026 5:38 pm
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump - Jul 9th, 2026 2:26 pm